DeepMed Research

JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of JNJ-70075200 in Healthy Participants

Phase 1

Withdrawn

Conditions: Healthy

Interventions: Drug: JNJ-70075200
Drug: Placebo

First Posted Date: 2021-03-04

Last Posted Date: 2022-01-05

Lead Sponsor: Janssen Research & Development, LLC

Registration Number: NCT04782661

Locations: 🇳🇱
PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen, Netherlands

A Study of JNJ-64304500 in Participants With Alopecia Areata

Phase 2

Withdrawn

Conditions: Alopecia Areata

Interventions: Drug: Placebo
Drug: JNJ-64304500

First Posted Date: 2021-02-05

Last Posted Date: 2021-05-04

Lead Sponsor: Janssen Research & Development, LLC

Registration Number: NCT04740970

Locations: 🇯🇵
The Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, Japan
🇯🇵
Yamaguchi University Hospital, Ube, Japan
🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

and more 19 locations

A Study of JNJ-64300535 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: JNJ-64300535

First Posted Date: 2021-02-03

Last Posted Date: 2021-12-22

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 14

Registration Number: NCT04736147

Locations: 🇧🇪
SGS Belgium NV, Edegem, Belgium

A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Teclistamab
Drug: Nirogacestat
Drug: Daratumumab
Drug: Lenalidomide
Drug: Pomalidomide
Drug: Bortezomib

First Posted Date: 2021-01-25

Last Posted Date: 2025-05-04

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 140

Registration Number: NCT04722146

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

and more 24 locations

A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Under Fed Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Darunavir
Drug: Cobicistat
Drug: Darunavir/Cobicistat FDC

First Posted Date: 2021-01-22

Last Posted Date: 2025-02-03

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 22

Registration Number: NCT04718805

Locations: 🇧🇪
SGS Clinical Pharmacology Unit (located in ZNA Stuivenberg), Antwerpen, Belgium

A Study of JNJ-64304500 Following Subcutaneous Injection in Healthy Chinese Adult Participants

Phase 1

Withdrawn

Conditions: Healthy

Interventions: Drug: JNJ-64304500

First Posted Date: 2021-01-15

Last Posted Date: 2021-09-01

Lead Sponsor: Janssen Research & Development, LLC

Registration Number: NCT04712006

Locations: 🇨🇳
Peking University Third Hospital, Beijing, China

A Study of Guselkumab in Adult Participants With Celiac Disease

Phase 1

Withdrawn

Conditions: Celiac Disease

Interventions: Drug: Guselkumab
Drug: Placebo

First Posted Date: 2021-01-12

Last Posted Date: 2025-02-03

Lead Sponsor: Janssen Research & Development, LLC

Registration Number: NCT04704843

Locations: 🇺🇸
West Michigan Clinical Research Center, Wyoming, Michigan, United States
🇺🇸
Hightower Clinical, Oklahoma City, Oklahoma, United States
🇺🇸
Clinical Trials Network, Lancaster, California, United States

and more 1 locations

A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

Phase 3

Completed

Conditions: Crohn Disease

Interventions: Drug: Ustekinumab
Drug: Placebo

First Posted Date: 2020-12-17

Last Posted Date: 2025-04-25

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 101

Registration Number: NCT04673357

Locations: 🇺🇸
Nemours DuPont Hospital for Children, Wilmington, Delaware, United States
🇺🇸
Children's Center for Digestive Health Care, Atlanta, Georgia, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 50 locations

Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

Phase 3

Completed

Conditions: X-Linked Retinitis Pigmentosa

First Posted Date: 2020-12-17

Last Posted Date: 2025-04-25

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 97

Registration Number: NCT04671433

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States
🇩🇰
Rigshospitalet Glostrup, Glostrup, Denmark

and more 24 locations

A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection

Phase 2

Completed

Conditions: Hepatitis B, Chronic

Interventions: Drug: JNJ-73763989
Drug: Tenofovir disoproxil
Drug: Tenofovir alafenamide (TAF)
Drug: Entecavir (ETV) monohydrate
Drug: PegIFN-alpha2a

First Posted Date: 2020-12-14

Last Posted Date: 2024-07-03

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 48

Registration Number: NCT04667104

Locations: 🇯🇵
Tokyo Medical and Dental University Hospital, Bunkyo Ku, Japan
🇯🇵
Osaka University Hospital, Suita-shi, Japan
🇵🇱
Przychodnia EuroMediCare Wroclaw Lowiecka, Wroclaw, Poland

and more 8 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy